DCA Metabolic Conditioning Creates Superior Cancer-Fighting T Cells
Redirecting glucose metabolism during T cell expansion dramatically improves cancer immunotherapy effectiveness.
20 articles
Redirecting glucose metabolism during T cell expansion dramatically improves cancer immunotherapy effectiveness.
Liquid biopsy using circulating tumor DNA shows promise for catching gastrointestinal cancer recurrence before symptoms appear.
Circulating tumor DNA testing identifies microscopic cancer remnants, predicting recurrence risk with remarkable accuracy.
Researchers respond to peer critique of risk-based, non-invasive hepatocellular carcinoma surveillance in metabolic liver disease patients.
New liquid biopsy technology offers minimally invasive cancer detection using simple blood draws instead of tissue biopsies.
Revolutionary blood tests can detect breast cancer changes in real-time without invasive tissue biopsies.
New circulating tumor DNA test identifies high-risk colon cancer patients with 80% accuracy, potentially revolutionizing treatment decisions.
Liquid biopsy with next-generation sequencing shows promise for predicting glioma patient outcomes through circulating tumor DNA analysis.
Revolutionary liquid biopsy technologies show promise for catching GI cancers early through simple blood tests, potentially saving millions of lives.
Large study reveals immune checkpoint inhibitors cause diabetes in 0.52% of patients, with 90% requiring hospitalization.
Revolutionary blood tests can detect cancer DNA fragments, enabling earlier diagnosis and better treatment monitoring.
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
New research reveals popular weight-loss medications may reduce cancer risk beyond their metabolic benefits.
Study identifies blood markers that distinguish long-term survivors from short-term survivors in brain cancer treatment.
Breakthrough biosensors analyze blood and other fluids to detect cancer biomarkers, offering faster, less invasive diagnosis than traditional methods.
Advanced biomarker combinations show 96% accuracy in detecting pancreatic cancer, significantly better than current standard tests.
Tumor cells in intrahepatic cholangiocarcinoma hijack IL-6 signaling to fuel growth โ creating a targetable metabolic vulnerability.
New AI framework analyzes cancer tissue samples 10x faster with 20x less data transfer, enabling real-time surgical decisions.
Comprehensive review reveals how rapid diagnostic devices could revolutionize neuroblastoma detection in children.
A new AI model spots pancreatic cancer on standard CT scans nearly 16 months before radiologists can see it โ with nearly 3x their sensitivity.